Global Allogeneic Cell Therapy Market Trends and Forecasts, 2023-2035, Featuring 378 Companies and Unveiling Key Regional Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Allogeneic Cell Therapy Market Trends and Forecasts, 2023-2035” report has been added to ResearchAndMarkets.com’s offering.

The global allogeneic cell therapy market is projected to witness significant growth in the coming years, with an estimated worth of USD 0.9 billion in 2023, projected to grow at a compounded annual growth rate (CAGR) of 14% during the forecast period from 2023 to 2035.

Key Insights

Allogeneic vs. Autologous Cell Therapy: Allogeneic cell therapy differs from autologous cell therapy, which uses a patient’s own cells. Allogeneic therapies offer immediate availability, scalability, and cost-effectiveness. However, they carry the risk of immune rejection. Autologous therapies, on the other hand, are personalized but require longer production times.

Pipeline and Clinical Trials: The allogeneic cell therapy landscape features around 195 companies developing treatments for various indications. Over 470 allogeneic cell therapies are in different stages of preclinical and clinical development. Notably, Gamida Cell received FDA approval for its allogeneic stem cell therapy, Omisirge, in April 2023, targeting hematologic malignancies.

Partnerships and Collaborations: Collaboration is a significant trend in the allogeneic cell therapy market, with over 90 partnerships established since 2019. Partnerships cover research, licensing, and development of allogeneic therapies. For example, Tessa Therapeutics partnered with the US National Cancer Institute for non-Hodgkin’s lymphoma treatment.

Funding and Investment: Investment in allogeneic cell therapy has been substantial, with nearly USD 8.8 billion invested globally over the past four years. Venture rounds have contributed to the majority of funds raised.

Market Growth Factors: The market is driven by the efforts of industry and non-industry players, the rising prevalence of chronic diseases, and the challenges associated with producing autologous cell therapies.

Clinical Trials: More than 365 clinical trials are evaluating allogeneic cell therapies for hematologic malignancies, solid tumors, infectious diseases, neurological disorders, and more.

Geographical Market Share: North America is anticipated to capture over 60% of the global allogeneic cell therapy market share by 2035. The region’s growth is attributed to rising disease incidence, FDA approvals, and government support for reimbursement.

Key Companies: Key players in the allogeneic cell therapy market include Artiva Biotherapeutics, Allogene Therapeutics, Atara Biotherapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Mesoblast, Poseida Therapeutics, and more.

Conclusion

The allogeneic cell therapy market is poised for substantial growth due to its benefits, increasing pipeline, clinical trial results, partnerships, and investments. Collaborative efforts, clinical advancements, and the growing demand for effective therapies across various indications are expected to drive the allogeneic cell therapy market’s expansion.

Key Topics Covered

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Partnerships and Collaborations

6. Funding and Investments

7. Clinical Trial Analysis

8. Key Opinion Leaders

9. Market Forecast and Opportunity Analysis

10. Executive Insights

11. Appendix I: Tabulated Data

12. Appendix II: List of Companies and Organizations

Companies Mentioned (378 Total)

• 920th Hospital of Joint Logistics Support Force
• AbbVie
• Academisch Medisch Centrum
• Acepodia
• Adaptimmune Therapeutics
• Adicet Bio
• Aegle Therapeutics
• Affiliated Hospital to Academy of Military Medical Sciences
• Affimed
• Alaunos Therapeutics
• Allogene Therapeutics
• AlloVir
• Alpha Biopharma
• Altaco XXI
• Amgen
• Angiocrine Bioscience
• Anhui Provincial Hospital
• Ann & Robert H. Lurie Children’s Hospital of Chicago
• Anterogen
• Antion Biosciences
• APICES
• Athersys
• Artiva Biotherapeutics
• Astellas Pharma
• Atara Biotherapeutics
• Athenex
• Athersys
• Autolomous
• Azidus Brasil
• Bayer
• Baylor College of Medicine
• Baylx
• Be The Match BioTherapies
• Beijing 302 Hospital
• Beijing Doing Biomedical
• Beijing GD Initiative Cell Therapy Technology
• Beijing Immunochina Medical Science & Technology
• JD Biotech
• Beijing SH biotechnology
• Beth Israel Deaconess Medical Center
• BHI Therapeutic Sciences
• BioCardia
• Bioceltech Therapeutics
• BioCentriq
• Biomedical Advanced Research and Development Authority (BARDA)
• Biorasi
• Bioray Laboratories
• BioSenic (Previously known as Bone Therapeutics)
• Bristol Myers Squibb
• California Institute for Regenerative Medicine
• and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/qop8z6

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900